ASH 2022 Post Conference Perspectives: Emerging Treatments in Multiple Myeloma

Saad Usmani, MD, MBA, FACP, discusses the MagnetisMM-1 trial data evaluating elranatamab in patients with relapsed or refractory multiple myeloma (RRMM) and reviews innovations that are needed to improve the management of RRMM.

Saad Usmani, MD, MBA, FACP, reviews the GEM-CESAR trial data presented at ASH 2022 on a potential curative strategy for high-risk smoldering myeloma and discusses his treatment strategy for this disease.

Saad Usmani, MD, MBA, FACP, discusses the health-related quality of life data from the GRIFFIN trial presented at ASH 2022 and reviews his key takeaways, including his thoughts on how health care decision-makers should act on these results.

Saad Usmani, MD, MBA, FACP, explores the burden of multiple myeloma on patient health-related quality of life [HRQoL] and why HRQoL results of clinical trials should be considered when making treatment decisions for this disease.

Saad Usmani, MD, MBA, FACP, discusses the unmet needs for multiple myeloma patients and the health-related quality of life (HRQoL) data and key takeaways from the MAIA trial presented at ASH 2022.